Global PSA Blood Based Biomarker Market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 1.2 billion by 2030 from USD 0.8 billion in 2018. The market is driven by factors such as increasing incidence of prostate cancer and rising awareness about prostate cancer screening among men, which are expected to drive the demand for PSA blood based biomarkers during the forecast period.
Screening biomarkers are used for early detection of prostate cancer and diagnosis biomarkers are used for diagnosing prostate cancer after it has been detected through screening or other means. Screening biomarkers have higher growth potential than diagnosis biomarkers due to their ability to detect early stages of disease progression and reduce mortality rates associated with advanced stage cancers. Diagnosis biomarkers have lower growth potential due to their limited use in detecting advanced stage cancers that require treatment options such as surgery or radiation therapy, which can be expensive and may not be covered by insurance providers in some countries like India where healthcare costs are high relative to income levels.
Some Of The Growth Factors Of This Market:
- The PSA blood based biomarker market is driven by the increasing incidence of prostate cancer, which is the most common cancer among men in the US.
- The PSA blood based biomarker market is also driven by the rising awareness about prostate cancer and its symptoms.
- Increasing prevalence of chronic diseases such as diabetes and obesity are also driving the growth of this market.
- Increasing government funding for research on prostate cancer.
Industry Growth Insights published a new data on “Prostate Specific Antigen (PSA) Blood Based Biomarker Market”. The research report is titled “Prostate Specific Antigen (PSA) Blood Based Biomarker Market research by Types (Screening Biomarker, Diagnosis Biomarker), By Applications (Diagnostics, Drug Discovery, Personalized Medicine, Others), By Players/Companies ProteoMediX, Cleveland Diagnostics, Randox, Roche, GENFIT, Nutech Cancer Biomarkers, OGT (Sysmex Group), Minomic, Creative Diagnostics”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Prostate Specific Antigen (PSA) Blood Based Biomarker Market Research Report
By Type
Screening Biomarker, Diagnosis Biomarker
By Application
Diagnostics, Drug Discovery, Personalized Medicine, Others
By Companies
ProteoMediX, Cleveland Diagnostics, Randox, Roche, GENFIT, Nutech Cancer Biomarkers, OGT (Sysmex Group), Minomic, Creative Diagnostics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
 Blood Based Biomarker Industry Outlook.svg)
Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Report Segments:
The global Prostate Specific Antigen (PSA) Blood Based Biomarker market is segmented on the basis of:
Types
Screening Biomarker, Diagnosis Biomarker
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diagnostics, Drug Discovery, Personalized Medicine, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ProteoMediX
- Cleveland Diagnostics
- Randox
- Roche
- GENFIT
- Nutech Cancer Biomarkers
- OGT (Sysmex Group)
- Minomic
- Creative Diagnostics
 Blood Based Biomarker Market Overview.svg)
Highlights of The Prostate Specific Antigen (PSA) Blood Based Biomarker Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Screening Biomarker
- Diagnosis Biomarker
- By Application:
- Diagnostics
- Drug Discovery
- Personalized Medicine
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Prostate Specific Antigen (PSA) Blood Based Biomarker Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Blood Based Biomarker Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Prostate specific antigen (PSA) is a blood based biomarker that can be used to help diagnose prostate cancer. PSA levels may increase in men with prostate cancer, and may also increase in men who have benign prostatic hyperplasia (BPH), which is a condition that affects the urinary tract.
Some of the major players in the prostate specific antigen (psa) blood based biomarker market are ProteoMediX, Cleveland Diagnostics, Randox, Roche, GENFIT, Nutech Cancer Biomarkers, OGT (Sysmex Group), Minomic, Creative Diagnostics.
The prostate specific antigen (psa) blood based biomarker market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Prostate Specific Antigen (PSA) Blood Based Biomarker Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Prostate Specific Antigen (PSA) Blood Based Biomarker Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Prostate Specific Antigen (PSA) Blood Based Biomarker Market - Supply Chain
4.5. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Forecast
4.5.1. Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size (000 Units) and Y-o-Y Growth
4.5.3. Prostate Specific Antigen (PSA) Blood Based Biomarker Market Absolute $ Opportunity
5. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Type
5.3.1. Screening Biomarker
5.3.2. Diagnosis Biomarker
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Application
6.3.1. Diagnostics
6.3.2. Drug Discovery
6.3.3. Personalized Medicine
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Demand Share Forecast, 2019-2026
9. North America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Application
9.4.1. Diagnostics
9.4.2. Drug Discovery
9.4.3. Personalized Medicine
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Type
9.7.1. Screening Biomarker
9.7.2. Diagnosis Biomarker
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Prostate Specific Antigen (PSA) Blood Based Biomarker Demand Share Forecast, 2019-2026
10. Latin America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Application
10.4.1. Diagnostics
10.4.2. Drug Discovery
10.4.3. Personalized Medicine
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Type
10.7.1. Screening Biomarker
10.7.2. Diagnosis Biomarker
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Prostate Specific Antigen (PSA) Blood Based Biomarker Demand Share Forecast, 2019-2026
11. Europe Prostate Specific Antigen (PSA) Blood Based Biomarker Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Application
11.4.1. Diagnostics
11.4.2. Drug Discovery
11.4.3. Personalized Medicine
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Type
11.7.1. Screening Biomarker
11.7.2. Diagnosis Biomarker
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Prostate Specific Antigen (PSA) Blood Based Biomarker Demand Share, 2019-2026
12. Asia Pacific Prostate Specific Antigen (PSA) Blood Based Biomarker Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Application
12.4.1. Diagnostics
12.4.2. Drug Discovery
12.4.3. Personalized Medicine
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Type
12.7.1. Screening Biomarker
12.7.2. Diagnosis Biomarker
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Prostate Specific Antigen (PSA) Blood Based Biomarker Demand Share, 2019-2026
13. Middle East & Africa Prostate Specific Antigen (PSA) Blood Based Biomarker Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Application
13.4.1. Diagnostics
13.4.2. Drug Discovery
13.4.3. Personalized Medicine
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Prostate Specific Antigen (PSA) Blood Based Biomarker Market Size and Volume Forecast by Type
13.7.1. Screening Biomarker
13.7.2. Diagnosis Biomarker
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Prostate Specific Antigen (PSA) Blood Based Biomarker Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Prostate Specific Antigen (PSA) Blood Based Biomarker Market: Market Share Analysis
14.2. Prostate Specific Antigen (PSA) Blood Based Biomarker Distributors and Customers
14.3. Prostate Specific Antigen (PSA) Blood Based Biomarker Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. ProteoMediX
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Cleveland Diagnostics
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Randox
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. GENFIT
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Nutech Cancer Biomarkers
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. OGT (Sysmex Group)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Minomic
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Creative Diagnostics
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
